In the past three months we’ve featured 11 emerging biotech startups — selected from the VentureRadar Database — working on a range new approaches to tackling major diseases. You can find out more about all the companies in the summaries below.
Cutanos
Cutanos is developing dermal targeted delivery systems for novel vaccines and immunotherapies via a modular antigen delivery platform that only targets Langerhans cells. Cutanos is working on antiviral vaccines and therapies for autoimmune diseases… [Read full post] [View VentureRadar Profile] [View Similar Companies to Cutanos]
NeuVasQ is aiming to repair neurovascular function in a range of neurodegenerative disorders by restoring the integrity of the blood-brain barrier (BBB). The company’s approach involves precisely targeting the pathways responsible for BBB formation, with the aim to restore lost functionality to the neurovasculature… [Read full post] [View VentureRadar Profile] [View Similar Companies to NeuVasQ Biotechnologies]
Tribune Therapeutics is developing novel biological drugs to treat patients with fibrotic diseases, including diseases affecting the kidney, lung and liver. Tribune’s medicines target the CCN protein family… [Read full post] [View VentureRadar Profile] [View Similar Companies to Tribune Therapeutics]
xFOREST Therapeutics is developing a platform for targeting disease-related RNA structures with small molecules. The company’s platform enables the search for highly specific RNA-binders, empowering the rapid and efficient discovery of RNA-targeting drugs… [Read full post] [View VentureRadar Profile] [View Similar Companies to xFOREST Therapeutics]
Angios is developing new treatments for challenging vascular diseases using the vascular organoid model developed by the company’s founders. The vascular organoids allow the company to model human microvascular complications in the dish and thereby find new pathways associated with disease progression… [Read full post] [View VentureRadar Profile] [View Similar Companies to Angios Biotech]
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases… [Read full post] [View VentureRadar Profile] [View Similar Companies to MoonLake Immunotherapeutics]
ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung diseases, carried out by company founder and Chief Scientific Officer C. Vivek Lal at University of Alabama at Birmingham… [Read full post] [View VentureRadar Profile] [View Similar Companies to ResBiotic]
Alchemab identifies naturally occurring protective antibodies that counter complex diseases, such as cancer and neurodegenerative diseases, by mining the antibody repertoires of individuals who are resistant to or recovered from disease… [Read full post] [View VentureRadar Profile] [View Similar Companies to Alchemab Therapeutics]
Wild Biotech is mining wild animal microbiomes for the discovery of novel human therapeutics. The company’s founders have sampled the faeces of 184 wild animals, including fish, birds, and mammals, from four different continents to discover more than 1,000 previously undescribed bacterial species and identified factors that correlate with the composition, diversity, and functional content of the microbiota… [Read full post] [View VentureRadar Profile] [View Similar Companies to Wild Biotech]
MUVON Therapeutics is developing an autologous cell therapy for the treatment of diseases related to skeletal muscle damage or degradation. The technology behind MUVON was developed over the past decade at the University of Zurich and in recent years… [Read full post] [View VentureRadar Profile] [View Similar Companies to MUVON Therapeutics]
Chimerna Therapeutics has developed a platform for generating circular RNA, which overcomes the major limitations of RNA therapeutics, namely stability and abundance. The company says this proprietary technology makes robust endogenous expression of RNAs and RNA aptamers possible… [Read full post] [View VentureRadar Profile] [View Similar Companies to Chimerna Therapeutics]